STUDY OBJECTIVES: Orexin peptides activate orexin 1 and orexin 2 receptors (OX(1)R and OX(2)R), regulate locomotion and sleep-wake. The dual OX(1)R/OX(2)R antagonist almorexant reduces activity and promotes sleep in multiple species, including man. The relative contributions of the two receptors in locomotion and sleep/wake regulation were investigated in mice. DESIGN: Mice lacking orexin receptors were used to determine the contribution of OX(1)R and OX(2)R to orexin A-induced locomotion and to almorexant-induced sleep. SETTING: N/A. PATIENTS OR PARTICIPANTS: C57BL/6J mice and OX(1)R(+/+), OX(1)R(-/-), OX(2)R(+/+), OX(2)R(-/-) and OX(1)R(-/-)/OX(2)R(-/-) mice. INTERVENTIONS: Intracerebroventricular orexin A; oral dosing of almorexant. MEASUREMENTS AND RESULTS: Almorexant attenuated orexin A-induced locomotion. As in other species, almorexant dose-dependently increased rapid eye movement sleep (REM) and nonREM sleep in mice. Almorexant and orexin A were ineffective in OX(1)R(-/-)/OX(2)R(-/-) mice. Both orexin A-induced locomotion and sleep induction by almorexant were absent in OX(2)R(-/-) mice. Interestingly, almorexant did not induce cataplexy in wild-type mice under conditions where cataplexy was seen in mice lacking orexins and in OX(1)R(-/-)/OX(2)R(-/-) mice. Almorexant dissociates very slowly from OX(2)R as measured functionally and in radioligand binding. Under non equilibrium conditions in vitro, almorexant was a dual antagonist whereas at equilibrium, almorexant became OX(2)R selective. CONCLUSIONS: In vivo, almorexant specifically inhibits the actions of orexin A. The two known orexin receptors mediate sleep induction by almorexant and orexin A-induced locomotion. However, OX(2)R activation mediates locomotion induction by orexin A and antagonism of OX(2)R is sufficient to promote sleep in mice.
STUDY OBJECTIVES:Orexin peptides activate orexin 1 and orexin 2 receptors (OX(1)R and OX(2)R), regulate locomotion and sleep-wake. The dual OX(1)R/OX(2)R antagonist almorexant reduces activity and promotes sleep in multiple species, including man. The relative contributions of the two receptors in locomotion and sleep/wake regulation were investigated in mice. DESIGN:Mice lacking orexin receptors were used to determine the contribution of OX(1)R and OX(2)R to orexin A-induced locomotion and to almorexant-induced sleep. SETTING: N/A. PATIENTS OR PARTICIPANTS: C57BL/6J mice and OX(1)R(+/+), OX(1)R(-/-), OX(2)R(+/+), OX(2)R(-/-) and OX(1)R(-/-)/OX(2)R(-/-) mice. INTERVENTIONS: Intracerebroventricular orexin A; oral dosing of almorexant. MEASUREMENTS AND RESULTS:Almorexant attenuated orexin A-induced locomotion. As in other species, almorexant dose-dependently increased rapid eye movement sleep (REM) and nonREM sleep in mice. Almorexant and orexin A were ineffective in OX(1)R(-/-)/OX(2)R(-/-) mice. Both orexin A-induced locomotion and sleep induction by almorexant were absent in OX(2)R(-/-) mice. Interestingly, almorexant did not induce cataplexy in wild-type mice under conditions where cataplexy was seen in mice lacking orexins and in OX(1)R(-/-)/OX(2)R(-/-) mice. Almorexant dissociates very slowly from OX(2)R as measured functionally and in radioligand binding. Under non equilibrium conditions in vitro, almorexant was a dual antagonist whereas at equilibrium, almorexant became OX(2)R selective. CONCLUSIONS: In vivo, almorexant specifically inhibits the actions of orexin A. The two known orexin receptors mediate sleep induction by almorexant and orexin A-induced locomotion. However, OX(2)R activation mediates locomotion induction by orexin A and antagonism of OX(2)R is sufficient to promote sleep in mice.
Authors: D N Jones; J Gartlon; F Parker; S G Taylor; C Routledge; P Hemmati; R P Munton; T E Ashmeade; J P Hatcher; A Johns; R A Porter; J J Hagan; A J Hunter; N Upton Journal: Psychopharmacology (Berl) Date: 2001-01-01 Impact factor: 4.530
Authors: M Kalogiannis; S L Grupke; P E Potter; J G Edwards; R M Chemelli; Y Y Kisanuki; M Yanagisawa; C S Leonard Journal: Eur J Neurosci Date: 2010-06-22 Impact factor: 3.386
Authors: J J Hagan; R A Leslie; S Patel; M L Evans; T A Wattam; S Holmes; C D Benham; S G Taylor; C Routledge; P Hemmati; R P Munton; T E Ashmeade; A S Shah; J P Hatcher; P D Hatcher; D N Jones; M I Smith; D C Piper; A J Hunter; R A Porter; N Upton Journal: Proc Natl Acad Sci U S A Date: 1999-09-14 Impact factor: 11.205
Authors: R M Chemelli; J T Willie; C M Sinton; J K Elmquist; T Scammell; C Lee; J A Richardson; S C Williams; Y Xiong; Y Kisanuki; T E Fitch; M Nakazato; R E Hammer; C B Saper; M Yanagisawa Journal: Cell Date: 1999-08-20 Impact factor: 41.582
Authors: Christopher J Winrow; Anthony L Gotter; Christopher D Cox; Scott M Doran; Pamela L Tannenbaum; Michael J Breslin; Susan L Garson; Steven V Fox; Charles M Harrell; Joanne Stevens; Duane R Reiss; Donghui Cui; Paul J Coleman; John J Renger Journal: J Neurogenet Date: 2011-04-08 Impact factor: 1.250
Authors: Michihiro Mieda; Jon T Willie; Junko Hara; Christopher M Sinton; Takeshi Sakurai; Masashi Yanagisawa Journal: Proc Natl Acad Sci U S A Date: 2004-03-16 Impact factor: 11.205
Authors: Olga Dergacheva; Akihiro Yamanaka; Alan R Schwartz; Vsevolod Y Polotsky; David Mendelowitz Journal: Am J Physiol Heart Circ Physiol Date: 2017-02-03 Impact factor: 4.733
Authors: Pascal Bonaventure; Sujin Yun; Philip L Johnson; Anantha Shekhar; Stephanie D Fitz; Brock T Shireman; Terry P Lebold; Diane Nepomuceno; Brian Lord; Michelle Wennerholm; Jonathan Shelton; Nicholas Carruthers; Timothy Lovenberg; Christine Dugovic Journal: J Pharmacol Exp Ther Date: 2015-01-12 Impact factor: 4.030
Authors: Rhîannan H Williams; Sarah W Black; Alexia M Thomas; Juliette Piquet; Bruno Cauli; Thomas S Kilduff Journal: Cereb Cortex Date: 2019-03-01 Impact factor: 5.357
Authors: Philip L Johnson; Lauren M Federici; Stephanie D Fitz; John J Renger; Brock Shireman; Christopher J Winrow; Pascal Bonaventure; Anantha Shekhar Journal: Depress Anxiety Date: 2015-08-19 Impact factor: 6.505